Should I buy or sell SELLAS Life Sciences Group stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SELLAS Life Sciences Group in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SLS shares. View SLS analyst ratings or view top-rated stocks .

What is SELLAS Life Sciences Group's stock price target for 2024?

1 analysts have issued 1-year price targets for SELLAS Life Sciences Group's shares. Their SLS share price targets range from $3.00 to $3.00. On average, they predict the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 125.6% from the stock's current price. View analysts price targets for SLS or view top-rated stocks among Wall Street analysts .

How have SLS shares performed in 2024?

SELLAS Life Sciences Group's stock was trading at $1.06 at the start of the year. Since then, SLS stock has increased by 25.5% and is now trading at $1.33. View the best growth stocks for 2024 here .

When is SELLAS Life Sciences Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our SLS earnings forecast .

How were SELLAS Life Sciences Group's earnings last quarter?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) announced its quarterly earnings data on Friday, November, 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.09.

What ETF holds SELLAS Life Sciences Group's stock?

Global X Copper Miners ETF holds 2,148,719 shares of SLS stock, representing 0.36% of its portfolio.

When did SELLAS Life Sciences Group's stock split?

Shares of SELLAS Life Sciences Group reverse split before market open on Friday, November 8th 2019. The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 7th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of SELLAS Life Sciences Group?

Shares of SLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:SLS

SELLAS Life Sciences Group (SLS) Stock Price, News & Analysis

→ REVEALED: Elon Musk’s Secret A.I. Facility? (From InvestorPlace) (Ad)

Free SLS Stock Alerts

$1.33

-0.01 (-0.75%)

(As of 04/15/2024 ET)

Compare

Today's Range: $1.27
▼
$1.37
50-Day Range: $0.68
▼
$1.55
52-Week Range: $0.50
▼
$1.91

Volume: 805,003 shs
Average Volume: 1.47 million shs
Market Capitalization: $74.84 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

Get SELLAS Life Sciences Group alerts:

SELLAS Life Sciences Group MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 125.6% Upside
$3.00 Price Target
Short Interest: Bearish
9.37% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.24 out of 5 stars

Medical Sector

783rd out of 929 stocks

Pharmaceutical Preparations Industry

358th out of 422 stocks

3.5

Analyst's Opinion

Consensus Rating
SELLAS Life Sciences Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
SELLAS Life Sciences Group has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
9.37% of the outstanding shares of SELLAS Life Sciences Group have been sold short.
Short Interest Ratio / Days to Cover
SELLAS Life Sciences Group has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in SELLAS Life Sciences Group has recently increased by 1.74%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
SELLAS Life Sciences Group does not currently pay a dividend.
Dividend Growth
SELLAS Life Sciences Group does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SLS.

3.3

News and Social Media Coverage

News Sentiment
SELLAS Life Sciences Group has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for SELLAS Life Sciences Group this week, compared to 1 article on an average week.
Search Interest
11 people have searched for SLS on MarketBeat in the last 30 days. This is an increase of 83% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added SELLAS Life Sciences Group to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, SELLAS Life Sciences Group insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.60% of the stock of SELLAS Life Sciences Group is held by insiders.
Percentage Held by Institutions
Only 17.38% of the stock of SELLAS Life Sciences Group is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of SELLAS Life Sciences Group is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of SELLAS Life Sciences Group is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

>>Check out what this A.I. Perfect Storm is<<

About SELLAS Life Sciences Group Stock (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.

SLS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SLS Stock News Headlines

April 6, 2024 | americanbankingnews.com

SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS)

March 28, 2024 | msn.com

SELLAS Life Sciences Group files for $200M mixed shelf

April 16, 2024 | InvestorPlace (Ad)

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

March 28, 2024 | globenewswire.com

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

March 27, 2024 | markets.businessinsider.com

Buy Rating for SELLAS Life Sciences Amid Positive AML Study Results and Strengthened Financials

March 26, 2024 | markets.businessinsider.com

SELLAS Phase 2a Study Of SLS009 In R/r AML Positive; Updates Phase 3 REGAL Study

March 26, 2024 | globenewswire.com

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

March 21, 2024 | wsj.com

SELLAS Life Sciences Group Inc.

April 16, 2024 | InvestorPlace (Ad)

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

March 19, 2024 | globenewswire.com

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

March 19, 2024 | globenewswire.com

SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET

March 16, 2024 | marketwatch.com

Sellas Life Sciences Shares Drop 31% After Direct Offering Prices

March 15, 2024 | msn.com

Geron, Graphite Bio, Immuneering among healthcare movers

March 15, 2024 | msn.com

SELLAS Life Sciences looks to raise $20M in a direct offering

March 15, 2024 | markets.businessinsider.com

Sellas Announces $20 Mln Registered Direct Offering, Concurrent Private Placement

March 15, 2024 | finance.yahoo.com

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

March 15, 2024 | globenewswire.com

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

March 12, 2024 | seekingalpha.com

Aadi Bioscience Q4 2023 Earnings Preview

March 10, 2024 | investing.com

Sellas Life Sciences Group Inc (SLS)

March 9, 2024 | finanznachrichten.de

SELLAS Life Sciences Group, Inc.: SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

March 8, 2024 | globenewswire.com

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

March 7, 2024 | finance.yahoo.com

SLS Mar 2024 4.000 put

March 1, 2024 | finance.yahoo.com

SELLAS Life Sciences Group, Inc. (SLS)

March 1, 2024 | globenewswire.com

SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference

February 29, 2024 | globenewswire.com

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time

February 22, 2024 | morningstar.com

SELLAS Life Sciences Group Inc

February 16, 2024 | ca.finance.yahoo.com

SLS Feb 2024 0.500 call

See More Headlines

Receive SLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SELLAS Life Sciences Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/12/2021
Today: 4/15/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:SLS
CUSIP: N/A
CIK: 1390478
Web: www.sellaslifesciences.com
Phone: (646) 200-5278
Fax: 441-400-2875
Employees: 17
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $3.00
High Stock Price Target: $3.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +125.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.36)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-37,340,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -2,405.54%
Return on Assets: -241.00%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.23
Quick Ratio: 0.23

Sales & Book Value

Annual Sales: $1 million
Price / Sales: 74.84
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.25) per share
Price / Book: -5.32

Miscellaneous

Outstanding Shares: 56,270,000
Free Float: 55,368,000
Market Cap: $74.84 million
Optionable: Not Optionable
Beta: 2.35

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. Angelos M. Stergiou M.D. (Age 48)
ScD h.c., Founder, President, CEO & Director
Comp: $921.99k
Mr. John Thomas Burns CPA (Age 39)
Senior VP & CFO
Comp: $338.45k
Ms. Stacy E. Yeung
VP, Associate General Counsel & Head of Compliance
Dr. Dragan Cicic M.D. (Age 61)
MBA, Senior Vice President of Clinical Development
Comp: $466.43k
Mr. Andrew Elnatan
VP and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls & Quality

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SLS Stock Analysis - Frequently Asked Questions

Should I buy or sell SELLAS Life Sciences Group stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SELLAS Life Sciences Group in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SLS shares.
View SLS analyst ratings or view top-rated stocks.
What is SELLAS Life Sciences Group's stock price target for 2024?: 1 analysts have issued 1-year price targets for SELLAS Life Sciences Group's shares. Their SLS share price targets range from $3.00 to $3.00. On average, they predict the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 125.6% from the stock's current price.
View analysts price targets for SLS or view top-rated stocks among Wall Street analysts.
How have SLS shares performed in 2024?: SELLAS Life Sciences Group's stock was trading at $1.06 at the start of the year. Since then, SLS stock has increased by 25.5% and is now trading at $1.33.
View the best growth stocks for 2024 here.
When is SELLAS Life Sciences Group's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our SLS earnings forecast.

How were SELLAS Life Sciences Group's earnings last quarter?: SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) announced its quarterly earnings data on Friday, November, 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.09.
What ETF holds SELLAS Life Sciences Group's stock?: Global X Copper Miners ETF holds 2,148,719 shares of SLS stock, representing 0.36% of its portfolio.
When did SELLAS Life Sciences Group's stock split?: Shares of SELLAS Life Sciences Group reverse split before market open on Friday, November 8th 2019. The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 7th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.
How do I buy shares of SELLAS Life Sciences Group?: Shares of SLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SLS) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial